| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H26N2O5.H2O |
| Molecular Weight | 428.4782 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CCC[C@@H](NC1=C(CC2=C(O)C(=CC=C2)C(=O)N(C)C)C(=O)C1=O)C3=CC=C(C)O3
InChI
InChIKey=OVPWPDFETBKAQQ-UNTBIKODSA-N
InChI=1S/C23H26N2O5.H2O/c1-5-7-17(18-11-10-13(2)30-18)24-19-16(21(27)22(19)28)12-14-8-6-9-15(20(14)26)23(29)25(3)4;/h6,8-11,17,24,26H,5,7,12H2,1-4H3;1H2/t17-;/m1./s1
| Molecular Formula | C23H26N2O5 |
| Molecular Weight | 410.4629 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Merck & Co. and Ligand Pharmaceuticals are collaborating in the development of navarixin, an oral CXCR2/CXCR1 antagonist, for the treatment of solid tumours. Navarixin is a potent, allosteric antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly. Navarixin has also been investigated for the treatment of asthma, chronic obstructive pulmonary disease, psoriasis, but this research has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.97 nM [IC50] | |||
| 43.0 nM [IC50] |
PubMed
Patents
Sample Use Guides
Psoriasis: Navarixin 30 mg administered orally once daily for 28 days.
Route of Administration:
Oral
